microdosing glp-1 schedule THE PROGRAM Microdosing GLP-1 and Accutane: What

10.1016/j.neuropharm.2019.107748 121

The substance liraglutide, under the brand name Saxenda, was introduced to the market in 2015 as the first GLP-1 RA approved as a treatment complementary to exercise and diet for weight control in patients with high BMI (obese or overweight with weight-related comorbidities) [3]

However, as observed in the SURPASS-5, daily insulin dose remained similar in participants randomized to TZP 5 and 10 mg and was mildly reduced in those assuming TZP 15 mg

In patients with MASLD and established CVD, GLP-1-based therapies are strongly supported as a cornerstone treatment addressing both hepatic and cardiometabolic disease burden simultaneously

The changes following Lixisenatide therapy in Parkinsons disease were slightly less than the clinically meaningful threshold